Abstract
The eukaryotic cell cycle via mitogen-activated protein kinase (MAPK) has been considered as an effective signaling cascade pathway for anticancer therapy. In addition to the MAPK signaling pathway, the Rat Sarcoma Virus (Ras)/Rapidly Accelerated Fibrosarcoma (Raf)/MAPK-ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway is a signaling cascade that has a crucial role to play in cell survival and development of cancer, especially breast cancer. Novel drugs and clinical trials need to be investigated, taking into consideration the already studied genetic defects related to genesis of tumors in certain populations. The present review provides novel insights into current anticancertreatments involving the MAPK pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Environmental Pathology, Toxicology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
